Atara partner requests FDA meeting on rejected therapy application Mar 3, 2026 08:06AM
Atara Biotherapeutics extends $9 million payment deadline to 2028 Feb 23, 2026 08:00AM
Canaccord Genuity Downgrades Atara Biotherapeutics (ATRA) to Hold Jan 13, 2026 06:19AM
FDA rejects Atara Biotherapeutics' EBVALLO drug application Jan 12, 2026 08:04AM
ATARA Biotherapeutics amends Pierre Fabre deal, adjusts milestone payments Jan 2, 2026 04:06PM


Dec 19, 2025 04:03AM Atara Biotherapeutics (ATRA) PT Raised to $25 at Canaccord Genuity
Nov 21, 2025 06:34AM Atara Biotherapeutics (ATRA) PT Raised to $18 at Mizuho
Nov 3, 2025 09:04AM Pierre Fabre takes over tabelecleucel drug application from Atara
Aug 18, 2025 06:25AM Atara Biotherapeutics (ATRA) PT Lowered to $16 at Mizuho
Aug 11, 2025 04:53PM ATARA Biotherapeutics (ATRA) Tops Q2 EPS by 19c
Jul 24, 2025 08:00AM FDA accepts Atara's resubmitted drug application with priority review
Jul 14, 2025 08:01AM Atara Biotherapeutics resubmits tab-cel application to FDA
May 15, 2025 05:09PM ATARA Biotherapeutics (ATRA) Tops Q1 EPS by 350c
May 15, 2025 08:31AM Atara Biotherapeutics (ATRA) prices $16 million offering
Jan 28, 2025 06:41AM H.C. Wainwright Reiterates Neutral Rating on Atara Biotherapeutics (ATRA)
Jan 27, 2025 04:38PM ATARA Biotherapeutics (ATRA) announces reduction in workforce impacting approximately 50% of employees
Jan 21, 2025 03:45PM Atara Biotherapeutics (ATRA) PT Lowered to $5 at Stifel
Jan 21, 2025 07:32AM ATARA Biotherapeutics (ATRA) Provides Update on Clinical Programs Related to EBVALLO and ATA3219
Jan 17, 2025 06:31AM Atara Biotherapeutics (ATRA) PT Lowered to $17 at Canaccord Genuity
Jan 16, 2025 08:56AM ATARA Biotherapeutics (ATRA) to Resume Trading at 9 am after receiving CRL from FDA
Jan 16, 2025 08:35AM ATARA Biotherapeutics (ATRA) receives Complete Response Letter for EBVALLOTM
Dec 20, 2024 06:42AM Rodman & Renshaw Starts Atara Biotherapeutics (ATRA) at Buy
Nov 13, 2024 09:10AM Atara Biotherapeutics (ATRA) PT Raised to $10 at Stifel
Sep 3, 2024 04:16PM ATARA Biotherapeutics (ATRA) Announces $36M Share and Warrant Offering at $8.25/sh
Aug 16, 2024 09:03AM Mizuho Upgrades Atara Biotherapeutics (ATRA) to Outperform
Aug 12, 2024 05:40PM ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 301c
Jul 17, 2024 09:01AM ATARA Biotherapeutics (ATRA) Announces U.S. FDA Acceptance and Priority Review of BLA for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Jun 17, 2024 08:00AM ATARA Biotherapeutics (ATRA) Announces 1-for-25 Reverse Stock Split